Effect of Chemotherapy Treatment on Serum Levels of Progranulin in Egyptian Acute Myeloid Leukemia Patients

Abstract

ML is characterized by clonal expansion of undifferentiated myeloid precursors, resulting in impaired hematopoiesis and bone marrow failure. The growth factor Progranulin has significant biological effects in different types of cancer. This protein is a regulator of tumorigenesis because it stimulates cell proliferation, migration, invasion, angiogenesis, malignant transformation, resistance to anticancer drugs, and immune evasion. Elevated PGRN levels have been associated with a wide range of different human malignancies such as carcinomas of the breast, ovary, liver, kidney, prostate and the brain. In patients with CLL, high PGRN plasma levels were strongly associated with adverse risk factors including unmutated IGHV status, expression of CD38 and ZAP-70, and poor risk cytogenetics. In MM it has been demonstrated in vitro to promote cell survival and confer resistance to dexamethasone treatment. In patients with malignant lymphoma, serum progranulin was significantly higher than normal controls. The aim of the study is to measure level of Progranulin in the serum of adult patients with acute myeloid leukemia and to correlate it with prognosis and clinical outcome. This study